Table 5. Hazard of outcomes among women with BRCA mutations who received HRT after RRBSO versus the ones who did not.
| Outcomes | HRT (n=153) | No HRT (n=176) | 95% CI | |
|---|---|---|---|---|
| Bone fractures | ||||
| Persons-years | 1,160.63 | 1,254.77 | - | |
| No. of events | 17 | 27 | - | |
| Crude HR | 0.68 | 1 | 0.37–1.25 | |
| Adjusted HR* | 0.88 | 1 | 0.43–1.81 | |
| Osteoporosis | ||||
| Persons-years | 1,208.40 | 1,325.64 | - | |
| No. of events | ≤5 | 17 | - | |
| Crude HR† | 0.29 | 1 | 0.11–0.78 | |
| No. of women who had DEXA scan | 59 | 93 | ||
| Osteoporosis | ||||
| Persons-years | 548.43 | 756.36 | - | |
| No. of events | ≤5 | 17 | - | |
| Crude HR† | 0.35 | 1 | 0.13–0.95 | |
HRT, hormone replacement therapy; RRBSO, risk-reducing bilateral salpingo-oophorectomy; CI, confidence interval; HR, hazard ratio; DEXA, dual-energy X-ray absorptiometry.
*Adjusted for age and breast cancer; †No covariates included due to low number of events.